October 2026 Biotech Catalysts: 12 FDA Dates & Phase 3 Readouts

CTX112 Phase 1 initial data

CTX112 · B-cell malignancies

CRISPR Therapeutics is presenting initial data from a Phase 1 trial of CTX112, an allogeneic CAR-T cell therapy for B-cell malignancies. This is an early-stage readout, but it's significant because CTX112 is designed to improve on existing CAR-T therapies by enhancing efficacy and reducing side effects. The data will show safety and preliminary efficacy in patients who have failed other treatments.

Positive safety and any signs of efficacy could boost CRISPR's stock, as it would validate their next-generation platform. However, Phase 1 data is preliminary, and the market will focus on safety signals like cytokine release syndrome. If the therapy shows a good response rate, it could set the stage for further development. Failure would be a setback but not fatal at this stage.

Potential accelerated approval filing for NTLA-2002 in HAE

NTLA-2002 · Hereditary angioedema (HAE)

Intellia is expected to file for accelerated approval of NTLA-2002, a CRISPR-based therapy for hereditary angioedema, a rare genetic disorder causing severe swelling attacks. This filing is based on promising Phase 1/2 data showing durable reduction in attacks. If approved, it would be the first CRISPR therapy for a non-blood disease, marking a major milestone.

The filing itself is a catalyst, as it confirms the regulatory path. If the FDA accepts the application, Intellia's stock could rise. The market will also look for any updates on the rolling submission. Approval is not guaranteed, but the data has been strong. A positive outcome would validate CRISPR's potential beyond rare diseases.

Phase 3 data for NBI-1065845 in MDD (first trial)

NBI-1065845 · Major Depressive Disorder (MDD)

Neurocrine is reporting Phase 3 data for NBI-1065845, an investigational drug for major depressive disorder. This is the first of two pivotal trials, and positive results would support a new treatment option for the millions of patients who don't respond to existing antidepressants. The drug works by a novel mechanism, which could differentiate it from current therapies.

If the trial meets its primary endpoint of reducing depression scores, Neurocrine's stock could jump, as it would validate a new mechanism and expand its CNS portfolio. Failure would be a major blow. The market will also assess safety, particularly any psychiatric side effects. Given the high unmet need, even a modest effect could be commercially successful, but the FDA will require consistent results across trials.

VCTX210 Type 1 diabetes Phase 1 update

VCTX210 · Type 1 diabetes

CRISPR Therapeutics will present an update on VCTX210, a gene-edited stem cell therapy for type 1 diabetes, at a major conference. This is an early-stage program, but it represents a potential functional cure for diabetes. The update will include data on safety, engraftment, and insulin production in patients.

If the therapy shows evidence of insulin production and good safety, CRISPR's stock could rise, as it would be a major step toward a cure. However, Phase 1 data is limited, and the market will look for durability and any adverse events. Positive signals could attract partnerships and funding. Failure would be disappointing but not unexpected at this stage.

VK2735 SC Phase 3 VENTURE enrollment completion

VK2735 · Obesity

Viking Therapeutics is announcing completion of enrollment in its Phase 3 VENTURE trial of subcutaneous VK2735 for obesity. This is a milestone that sets the stage for topline data, likely in 2027. The announcement confirms the trial is on track and may include details on patient numbers and demographics.

The completion of enrollment is a positive signal, but it's not a major catalyst. The stock may see a slight bump as it de-risks the program. The market will focus on the timeline for data readout. Any delays would be negative. This is a routine update, but it keeps the stock in play.

Phase 3 data for ONC-392 in NSCLC

ONC-392 · Non-small cell lung cancer (NSCLC)

BioNTech is releasing Phase 3 data for ONC-392, an anti-CTLA-4 antibody, in non-small cell lung cancer. This is a pivotal readout that could position ONC-392 as a potential new treatment option for NSCLC, a large market. The data will show if the drug improves survival compared to standard of care, and positive results could significantly boost BioNTech's oncology pipeline beyond its COVID vaccine franchise.

If the trial meets its primary endpoint of overall survival, expect a significant stock rally as ONC-392 could become a major revenue driver. If it fails, shares could drop sharply. The market will also look at safety data and any subgroup analyses. Given the high unmet need in NSCLC, even modest efficacy could be viewed positively, but a clear benefit over existing therapies is needed for a strong commercial launch.

Panorama Phase 3 topline data for DT120 ODT in GAD

DT120 ODT (formerly MM120) · Generalized anxiety disorder (GAD)

MindMed is reporting topline results from its Phase 3 Panorama trial of MM120 (lysergide) for generalized anxiety disorder. This is a pivotal study that could lead to the first psychedelic-based treatment for GAD. The trial compares MM120 to placebo, and positive results would validate the therapeutic potential of psychedelics in mental health, a field with high interest but also high regulatory hurdles.

A positive outcome with significant improvement on the Hamilton Anxiety Scale and good safety could send MindMed's stock soaring, as it would be a major milestone for psychedelic medicine. Failure would be a severe setback. The market will also watch for durability of effect and any adverse events. Given the high prevalence of GAD, even a modest effect size could be commercially viable, but the FDA will require robust evidence.

mRNA-4157/V940 personalized cancer vaccine Phase 3 update

mRNA-4157 · Melanoma (adjuvant)

Moderna will present an update on its personalized cancer vaccine mRNA-4157 in combination with Keytruda for adjuvant melanoma. This is a Phase 3 trial, and the update will likely include efficacy and safety data. The vaccine is tailored to each patient's tumor mutations, and positive results could revolutionize cancer treatment.

If the update shows improved recurrence-free survival compared to Keytruda alone, Moderna's stock could jump. The market will also look for any safety issues. Given the promising Phase 2 data, expectations are high. A negative update would be a major setback for the program and the field of personalized vaccines.

Phase 3 data for vutrisiran in ATTR amyloidosis with cardiomyopathy

Vutrisiran · ATTR amyloidosis with cardiomyopathy

Alnylam is reporting Phase 3 data for vutrisiran, an RNAi therapy, in patients with ATTR amyloidosis and cardiomyopathy. This is a pivotal readout that could expand vutrisiran's label beyond polyneuropathy. The trial tests whether the drug reduces mortality and cardiovascular events, and positive results would position it as a major treatment for this fatal disease.

If the trial shows a significant reduction in mortality and hospitalizations, Alnylam's stock could jump, as it would solidify vutrisiran as a standard of care. The market will also assess safety. Failure would be a major setback, especially given the drug's success in polyneuropathy. The data will be compared to competitors like Pfizer's tafamidis.

Phase 3 interim analysis for mRNA-1083 flu+COVID combo vaccine

mRNA-1083 · Influenza and COVID-19 combination vaccine

Moderna is releasing interim data from a Phase 3 trial of mRNA-1083, a combination vaccine targeting both flu and COVID-19. This is a key step toward a single annual shot that could simplify vaccination schedules. The interim analysis will assess immunogenicity and safety, and positive results could lead to regulatory submissions and a major new product for Moderna.

If the combo vaccine shows non-inferior immune responses compared to separate vaccines and a good safety profile, Moderna's stock could rise as it strengthens its vaccine franchise. Failure or weak data would be a setback. The market will also look at the flu component's efficacy against circulating strains. Given the seasonal nature, timing of approval is critical for the 2027 flu season.

Phase 3 data for suzetrigine in diabetic peripheral neuropathy

Suzetrigine · Diabetic peripheral neuropathy (DPN)

Vertex is reporting Phase 3 data for suzetrigine, a non-opioid pain drug, in diabetic peripheral neuropathy. This is a pivotal readout that could provide a new treatment for chronic pain without the risks of opioids. The drug targets a specific sodium channel, and positive results would be a major advance in pain management.

If the trial shows significant pain relief and good safety, Vertex's stock could rise, as it would open a massive market. The market will also look for any adverse events, especially cardiac. Failure would be a setback, but Vertex has other programs. Given the opioid crisis, a non-addictive painkiller is highly sought after.

Phase 2 data for NBI-1117568 in Bipolar I Disorder

NBI-1117568 · Bipolar I Disorder

Neurocrine is reporting Phase 2 data for NBI-1117568, a muscarinic receptor agonist, in bipolar I disorder. This is an early-stage readout, but it could provide a new treatment option for bipolar depression. The data will show efficacy and safety, and positive results would support further development.

If the drug shows significant improvement in depression scores and is well-tolerated, Neurocrine's stock could see a modest bump. Failure would be a setback but not catastrophic. The market will compare to existing treatments like lithium and atypical antipsychotics. Given the need for better options, positive data could be meaningful.